Alzamend’s lithium-delivery system, licensed from the University of South Florida Research Foundation, aims to overcome currently experienced toxicities associated with lithium. Image credit: Shutterstock/Benjavisa Ruangvaree Art.

US-based biopharma company Alzamend Neuro has submitted an investigational new drug (IND) application to the US Food and Drug Administration (FDA) for the initiation of a Phase IIa trial with its AL001 candidate for bipolar disorder treatment.

The company is exploring the use of its patented ionic cocrystal technology, which delivers lithium via a therapeutic combination of lithium, proline and salicylate.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Lithium is considered the gold-standard treatment for bipolar disorder, but Alzamend says that it is potentially underutilised because of the need for therapeutic drug monitoring due to the treatment’s narrow operating window.

Licensed from the University of South Florida Research Foundation, Alzamend’s lithium-delivery system aims to overcome currently experienced toxicities associated with lithium. The company has already identified a maximum tolerated dose via a recently completed multiple ascending dose Phase IIa study in patients with Alzheimer’s disease. The dose, which is 240mg three times a day, is unlikely to require therapeutic drug monitoring and also helps distribute more lithium to the brain, Alzamend claims.

If approved by the FDA, Alzamend will use the upcoming Phase IIa study to observe the relatively increased levels of lithium in the brain when treated with AL001 compared to marketed lithium salt. The company plans to use its system to deliver 20% less lithium daily to patients.

Alzamend’s CEO Stephan Jackman said: “This IND submission represents a key milestone for Alzamend as we continue to advance our proprietary pipeline.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Being able to develop a next-generation lithium product (AL001) that would not routinely require TDM could positively impact the seven million Americans afflicted with BD. We look forward to providing more details regarding the study’s timeline and market opportunity in the near future.”